Lion's Mane for Cognitive Function
Lion's Mane is the most studied dietary mushroom for cognitive function in humans, anchored by a landmark 2009 Japanese double-blind placebo-controlled trial in adults aged 50 to 80 with mild cognitive impairment (Mori et al.). The Mori trial used 3 grams per day of 96% Lion's Mane fruit-body powder for 16 weeks and showed progressive cognitive improvement on the Hasegawa Dementia Scale-Revised (HDS-R) at weeks 8, 12, and 16, with regression by week 20 (four weeks after discontinuation) — a time course consistent with sustained neurotrophic support of vulnerable cholinergic neurons. The Saitsu 2019 trial, in healthy adults over 50 with normal cognitive function, found a significant improvement on one of its three tests, the Mini-Mental State Examination. In East Asia, Lion's Mane has been called the "smart mushroom" or "study mushroom" (in Japanese, yamabushitake — "mountain priest mushroom") and used as a tonic by Buddhist mountain priests, Chinese scholars, and Japanese college students preparing for examinations. This page synthesizes the human trial evidence, the time course, the practical question of which preparation produces measurable benefit, and the limitations of what we can and cannot yet claim.
Table of Contents
- The Mori 2009 Mild Cognitive Impairment Trial
- The Saitsu 2019 Elderly Cognitive Trial
- Additional Human Trials
- The "Smart Mushroom" / "Study Mushroom" Tradition
- Time Course: Why It Takes 8-12 Weeks
- Mild Cognitive Impairment in Context
- Which Preparation Produces Measurable Benefit
- Animal Evidence: Spatial Memory and Alzheimer's Models
- Lion's Mane in Young Healthy Adults — What We Know
- Combinations and Stacks
- Limitations of the Current Evidence
- Key Research Papers
- Connections
- Featured Videos
The Mori 2009 Mild Cognitive Impairment Trial
The pivotal human cognitive trial of Lion's Mane is Mori K et al. (2009), "Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial," published in Phytotherapy Research. The trial design was rigorous by the standards of nutritional supplement research:
- Population: Japanese men and women aged 50 to 80 years diagnosed with mild cognitive impairment (MCI); after 2 weeks of preliminary examination, 30 subjects were randomized into two groups of 15
- Intervention: Four 250 mg tablets of 96% Hericium erinaceus fruit-body powder, three times per day with meals (3,000 mg/day total)
- Control: Identical-appearance placebo tablets
- Duration: 16 weeks of supplementation, followed by 4 weeks washout
- Design: Randomized double-blind placebo-controlled
- Primary outcome: Hasegawa Dementia Scale-Revised (HDS-R) — a validated 30-point Japanese cognitive screening instrument similar to the Mini-Mental State Examination (MMSE), assessing orientation, registration, attention, recall, and language
The results showed a striking pattern. At weeks 8, 12 and 16 the Lion's Mane group scored significantly higher than the placebo group on the HDS-R-based cognitive function scale, and its scores increased with the duration of intake.
The most telling finding was the washout: 4 weeks after the 16 weeks of intake ended (week 20), the Lion's Mane group's scores had decreased significantly. This regression-on-discontinuation pattern is consistent with a sustained neurotrophic effect — benefit accumulating with continued nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) support of vulnerable neurons and dissipating when that support is withdrawn.
On safety, the authors report that laboratory tests showed no adverse effect of Lion's Mane.
The trial was small (30 participants split between two arms) and conducted in a single ethnic population in Japan, but the significant between-group difference at weeks 8, 12 and 16, the decline after discontinuation, and the absence of adverse laboratory findings have driven the substantial subsequent research interest in Lion's Mane for cognitive applications.
The Saitsu 2019 Elderly Cognitive Trial
The second major human cognitive trial of Lion's Mane was Saitsu Y et al. (2019), "Improvement of cognitive functions by oral intake of Hericium erinaceus," published in Biomedical Research. The Saitsu trial used a different design and a different cognitive battery:
- Population: healthy Japanese adults over 50 years old with normal cognitive function (the authors excluded one person whose starting MMSE score was below 24); 31 of 34 participants were analysed — unlike Mori 2009, this was not a mild cognitive impairment population
- Intervention: 3.2 g/day of Lion's Mane fruit-body powder (four supplements of 0.8 g) for 12 weeks
- Outcomes: Three tests: the Mini-Mental State Examination (MMSE), the Benton visual retention test, and the Standard verbal paired-associate learning test (S-PA)
Of the three tests, only the MMSE showed a benefit: in the authors' words, “MMSE alone showed that oral intake of H. erinaceus significantly improved cognitive functions and prevented from the deterioration”. The Benton visual retention test showed no significant change in either group and no difference between them, and for the S-PA the authors report “no significant changes in the test period and no significant changes between the two groups either”. The trial therefore adds a positive signal on one test, in people without cognitive impairment, rather than a full replication of the Mori result.
A handful of smaller cognitive trials have followed, including investigations of dual-extract preparations and of erinacine-A-enriched mycelium specifically. The overall pattern of small but consistent cognitive benefit in older adults has held up, though no single trial has yet been large enough to provide definitive evidence by pharmaceutical-research standards.
Additional Human Trials
Beyond the two pivotal cognitive trials, the human evidence base for Lion's Mane includes:
- Nagano M et al. (2010) — the menopausal-women mood trial discussed on the Mood and Depression page. Thirty women took Lion's Mane or placebo cookies for 4 weeks. The Indefinite Complaints Index score fell after intake within the Lion's Mane group, but compared with placebo only two of its items (“insentive” and “palpitatio” in the paper's wording) were significantly lower; “concentration”, “irritating” and “anxious” only tended to be lower.
- Vigna L et al. (2019) — an Italian study of Lion's Mane supplementation in 77 volunteers with overweight or obesity on a low-calorie diet. Eight weeks of supplementation decreased depression, anxiety and sleep disorders, and increased circulating pro-BDNF without a significant change in BDNF. Its outcomes were mood, sleep and binge eating, not cognition.
- Open-label observational data — several uncontrolled case series and open-label investigations have reported subjective cognitive benefit, particularly attention, word-finding, and processing speed. These reports are not high-quality evidence on their own but are consistent with the controlled-trial findings.
- Erinacine-A-enriched mycelium (Li IC et al. 2020) — a Taiwanese pilot double-blind placebo-controlled trial in patients with mild Alzheimer's disease. Patients took three 350 mg capsules a day (containing 5 mg/g erinacine A) or identical-looking placebo capsules for 49 weeks. Mini-Mental State Examination scores improved significantly in the treated group, Cognitive Abilities Screening Instrument scores fell significantly in the placebo group, and Instrumental Activities of Daily Living scores differed significantly between the groups. Brain-derived neurotrophic factor did not rise with treatment; it fell significantly only in the placebo group. Four people dropped out because of abdominal discomfort, nausea and skin rash. No erinacine-A trial in mild cognitive impairment was found in PubMed.
The next generation of trials, currently underway or in planning, will use larger sample sizes, longer follow-up, more sensitive cognitive batteries (computerised cognitive test batteries that can detect smaller cognitive changes than the HDS-R or MMSE), and preparations with characterized hericenone and erinacine content. The expected publication of these results over the next 2-3 years may substantially clarify whether Lion's Mane warrants disease-modifying claims in mild cognitive impairment and early Alzheimer's disease.
The "Smart Mushroom" / "Study Mushroom" Tradition
Lion's Mane has been used in East Asian traditional medicine for at least 1,000 years and possibly longer. Its three traditional uses, all attested in classical Chinese and Japanese herbal texts, are:
- Brain tonic for memory and focus — recommended to scholars, civil-service examination candidates, and students. In Japan it is called yamabushitake ("mountain priest mushroom") after the Buddhist mountain priests (yamabushi) who used it to support meditation and clarity during long ascetic retreats. In Chinese it is called hou tou gu ("monkey head mushroom") from its visual resemblance. In modern Chinese and Japanese student culture it is informally called the "study mushroom" or "smart mushroom" and is consumed in tea, soup, and traditional dishes during examination preparation.
- Digestive remedy for gastritis and stomach complaints — recommended for chronic indigestion, stomach pain, and what would now be recognized as peptic ulcer disease. See the Gut Health page.
- General longevity tonic — consumed as a soup or tea in old age to support overall health, energy, and resistance to fatigue.
The traditional cognitive use is the one with the most modern scientific validation: contemporary research has confirmed the NGF and brain-derived neurotrophic factor (BDNF) mechanism that plausibly underlies the historical "brain tonic" reputation. The ancient empirical observation (Lion's Mane supports memory) and the modern molecular mechanism (hericenones and erinacine A induce neurotrophin synthesis) point in the same direction.
Traditional culinary preparations — Lion's Mane sauteed with soy and ginger, in miso soup, or as part of a vegetable hot pot — deliver the full hericenone content along with the polysaccharides and beta-glucans of the whole fruit body. The traditional dose would have been one or two servings per week (Lion's Mane was not historically as commonplace as button or shiitake mushrooms) which by modern dry-weight calculation is in the low end of the trial-effective dose range. The traditional use was likely cumulative over years of intermittent consumption rather than acute pharmacological loading.
Time Course: Why It Takes 8-12 Weeks
One of the most clinically important features of Lion's Mane cognitive effects is the slow onset. The Mori 2009 trial showed no measurable difference between Lion's Mane and placebo at the 4-week assessment. The signal appeared at week 8, strengthened at week 12, and continued to grow through week 16. The Saitsu 2019 trial showed similar slow accumulation of effect over 12 weeks. The Tsai-Teng 2016 study in APPswe/PS1dE9 transgenic mice measured pathological benefit after 30 days of oral administration, and a behavioural (nesting) benefit after 81 days.
This is the time course expected of a neurotrophic mechanism, not a pharmacological one. Consider the mechanistic chain:
- Hericenones and erinacine A reach their target neurons (peripheral and central)
- These compounds induce transcription of NGF (and likely brain-derived neurotrophic factor) genes in astrocytes and neurons
- NGF/BDNF protein is synthesized and secreted
- NGF binds its receptor TrkA (tropomyosin receptor kinase A) on basal forebrain cholinergic neurons (and brain-derived neurotrophic factor binds TrkB, tropomyosin receptor kinase B, on hippocampal neurons), driving survival, axon growth, and dendritic remodeling
- These cellular changes (which take weeks to manifest at the circuit level) eventually produce measurable improvement in cognitive performance
Compare this to a fast-onset cognitive intervention like caffeine, which acts within 30-60 minutes by directly blocking adenosine receptors. Or to a slower but still relatively fast intervention like a selective serotonin reuptake inhibitor, which begins to produce measurable mood change at 2-4 weeks via gradual postsynaptic adaptation. Lion's Mane is slower still: 8-16 weeks for measurable cognitive change in older adults with mild cognitive impairment.
The clinical implication is that a short trial of Lion's Mane is uninformative. A 2-week or 4-week test will show nothing whether the person is a responder or not. In the Mori trial the difference from placebo first appeared at week 8, so a judgment formed before 8-12 weeks of consistent daily use comes before the point at which the trial saw any effect.
Mild Cognitive Impairment in Context
Mild Cognitive Impairment (MCI) is the diagnostic category between normal age-related cognitive change and frank dementia. Ronald C. Petersen at the Mayo Clinic codified the modern criteria in the 1990s. MCI is defined by:
- Subjective complaint of memory or cognitive change, ideally corroborated by a family member or partner
- Objective evidence of cognitive impairment on formal testing, typically scoring more than 1.5 standard deviations below age-matched norms on at least one cognitive domain
- Preserved general cognitive function (does not yet meet dementia criteria)
- Intact basic activities of daily living (can still manage finances, transport, medications, etc.)
- Not better explained by another condition (depression, medication side effect, sleep disorder)
MCI is clinically important because approximately 10-15% of MCI cases convert to dementia (most commonly Alzheimer's disease) each year. After 5 years, roughly half of all MCI cases have converted. Some cases remain stable; a minority improve. The MCI window represents the last opportunity for intervention before frank dementia is established.
Conventional medical care for MCI focuses on cardiovascular risk reduction (hypertension, diabetes, atrial fibrillation), modifiable lifestyle factors (sleep, exercise, social engagement, diet, smoking), screening for and treating depression and obstructive sleep apnea, and review of cognitively-impairing medications (anticholinergics, benzodiazepines, opioids, sedating antihistamines). The cholinesterase inhibitor drugs (donepezil, rivastigmine, galantamine) are formally approved only for Alzheimer's dementia, not for MCI, though some clinicians prescribe them off-label in MCI on the theory that earlier intervention may delay conversion.
Lion's Mane is not a replacement for the conventional interventions above — cardiovascular risk reduction in particular has the strongest evidence base for reducing dementia incidence at the population level. The human trial evidence specific to MCI is the 30-person Mori 2009 trial, with no adverse laboratory findings; the Saitsu 2019 trial enrolled people with normal cognitive function. See the Dementia page for the comprehensive approach.
Which Preparation Produces Measurable Benefit
The Mori 2009 trial that established the cognitive evidence base used 96% Lion's Mane fruit-body powder at 3 grams per day. That specific preparation and dose remain the best-validated for the cognitive indication.
Three product categories are commercially available:
- Fruit-body extract — closest to the Mori 2009 preparation. Delivers hericenones and polysaccharides. The traditional whole-mushroom approach. Fruit-body powder was the form used in the Mori 2009 and Saitsu 2019 trials.
- Erinacine-A-enriched mycelium — mycelium grown in controlled conditions to induce erinacine production, extracted and concentrated. Delivers erinacine A, which crosses the blood-brain barrier, but lacks the fruit-body hericenones. Preferred by some advocates for central nervous system applications because of that blood-brain barrier crossing.
- Dual extract (fruit body + mycelium-without-grain) — combines both, delivering both compound families. Cost is higher.
The weakest category is cheap mycelium-on-grain products that do not specify their composition. These are commonly described as containing 60-80% residual rice or oat grain by weight; the actual mushroom-derived bioactive content may be a small fraction of the labeled product weight. Beta-glucan testing is one quality marker (fruit-body extracts are commonly described as testing at 25% or higher beta-glucan, and many mycelium-on-grain products below 10%). Products whose makers publish third-party testing certificates and disclose fruit-body and mycelium content separately give buyers the most information.
Fresh culinary Lion's Mane fruit body is an excellent option for people who can find it (specialty grocery stores in the U.S. and Canada since the late 2010s, farmers' markets, Asian supermarkets, and home growing). A meaningful weekly portion (200-300 g fresh, equivalent to 20-30 g dry weight) provides hericenones at doses likely sufficient for at least the peripheral effects, and the experience of eating the whole-food mushroom is pleasant. The texture resembles crab meat or scallop and the flavor is mild and savory; it takes well to sauteing in butter or olive oil.
Animal Evidence: Spatial Memory and Alzheimer's Models
Beyond the human trial evidence, the animal model literature for Lion's Mane cognitive effects is extensive and consistent. The most influential studies are:
- Tsai-Teng et al. 2016 (APPswe/PS1dE9 model) — after 30 days of oral administration to female transgenic mice (a mouse model of familial Alzheimer's disease), erinacine-A-enriched mycelium and its ethanol extract reduced amyloid-beta plaque burden, raised insulin-degrading enzyme, reduced plaque-activated microglia and astrocytes, raised the ratio of nerve growth factor to its precursor (proNGF) and promoted hippocampal neurogenesis. After 81 days of dosing, the mycelium restored the nesting behaviour (a mouse measure of daily-living skills) that declines in these mice. This is the single most influential preclinical Alzheimer's study of Lion's Mane.
- Mori et al. 2011 (amyloid-beta 25-35 infusion model) — oral Lion's Mane fruit-body powder prevented learning and memory deficits induced by intracerebroventricular injection of the amyloid-beta 25-35 peptide fragment in mice.
- Scopolamine-induced amnesia models — multiple groups have shown that pretreatment with Lion's Mane preparations attenuates the cognitive impairment induced by scopolamine (a muscarinic acetylcholine receptor blocker) in mice and rats. This is consistent with cholinergic system support.
- Aging and senescence-accelerated mouse models — Lion's Mane preparations have shown cognitive and neuroprotective benefit in SAMP8 senescence-accelerated mice and in aged wild-type mice.
- Stroke and ischemia models — pretreatment or post-treatment with Lion's Mane has shown neuroprotective effect in middle cerebral artery occlusion models of stroke.
Animal evidence does not automatically translate to human benefit, particularly in neurodegenerative disease where mouse models have notoriously poor predictive validity for human Alzheimer's drug development. But the consistency of the Lion's Mane animal data — multiple groups, multiple models, multiple endpoints, multiple preparations — provides reasonable preclinical support for the human trial findings.
Lion's Mane in Young Healthy Adults — What We Know
A frequent question is whether Lion's Mane produces cognitive benefit in young healthy adults — the nootropic-stack and college-student demographic that drives much of the U.S. supplement market.
The honest answer is: the evidence is weaker than for older adults. The Mori 2009 trial enrolled adults aged 50 to 80 with mild cognitive impairment; the Saitsu 2019 trial enrolled healthy adults over 50 with normal cognitive function. The mechanism — NGF/BDNF support of neurons that are under degenerative stress — predicts a smaller absolute effect in young healthy adults whose neurons are not yet under degenerative stress.
Small trials in young healthy adults have produced mixed results. A 2023 randomized double-blind pilot trial in 41 healthy adults aged 18-45 tested 1.8 g of Lion's Mane: participants were quicker on the Stroop task 60 minutes after a single dose (p = 0.005), and after 28 days there was a trend towards lower subjective stress (p = 0.051), alongside “null and limited negative findings”. A 2025 randomized double-blind crossover study gave 18 healthy adults aged 18-35 a single 3 g dose of a 10:1 fruiting-body extract and found no significant effect on composite measures of global cognitive function and mood 90 minutes later; only the pegboard test improved. The popular "Lion's Mane improves focus and memory in young students" claim outruns the actual published evidence. Some young adults report subjective improvement in focus, word-finding, and clarity. Others report no detectable effect. The slow-onset kinetic makes informal personal experimentation difficult: it requires 8-12 weeks of consistent dosing before any judgment is informative, longer than most casual self-experimenters maintain.
In summary: in young healthy adults the trial evidence is limited to small, short studies with mixed results. Lion's Mane is not a replacement for sleep, exercise, social engagement, or sustained intellectual challenge, which remain the most powerful interventions for cognitive function in this demographic. The evidence in older adults does not automatically generalize to young healthy adults.
Combinations and Stacks
Lion's Mane is frequently combined with other cognitive-supportive nutrients and supplements. Common combinations include:
- Lion's Mane + Omega-3 (eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA)) — omega-3 fatty acids, particularly docosahexaenoic acid, are structural components of neuronal membranes and have independent evidence for cognitive support in older adults. The combination addresses different mechanisms (neurotrophic support vs membrane fluidity) and is well-tolerated. See the Omega-3 Fatty Acids page.
- Lion's Mane + B-complex (B6, B9 folate, B12) — B-vitamin deficiency is a common reversible cause of cognitive complaint in older adults, particularly B12 (often deficient on plant-based diets or with proton pump inhibitor use). Repletion of any deficiency is foundational before evaluating any neurotrophic supplement effect.
- Lion's Mane + Vitamin D — vitamin D deficiency is independently associated with cognitive impairment in older adults. Repletion is foundational. See the Vitamin D3 page.
- Lion's Mane + adaptogenic herbs (Ashwagandha, Rhodiola) — the adaptogenic herbs address stress and hypothalamic-pituitary-adrenal (HPA) axis dysregulation, which contribute to cognitive complaints in many adults. The combination is well-tolerated. See the Ashwagandha page.
- Lion's Mane + Reishi, Turkey Tail, or Chaga (other functional mushrooms) — multi-mushroom blends are widely marketed for general immune and metabolic support; for cognitive purposes specifically, Lion's Mane is the one of these with human cognitive-trial data.
Proprietary blends that combine Lion's Mane with a long list of unfocused nootropic ingredients — racetams, choline donors at high doses, or experimental compounds — add ingredients with unknown long-term safety profiles. Simple, well-characterized combinations carry fewer unknowns.
Limitations of the Current Evidence
An honest summary of what we cannot yet claim:
- The trials in older adults are small. Mori 2009 (mild cognitive impairment) had 30 participants total. Saitsu 2019 (normal cognitive function) analysed 31. These are small studies by pharmaceutical-research standards and the findings need replication in larger samples.
- Cross-cultural generalization is untested. Both pivotal trials enrolled exclusively Japanese participants. Genetic, dietary, and microbiome differences between East Asian and Western populations may affect Lion's Mane response.
- Long-term effects beyond 16 weeks are unknown. Whether benefits continue to accumulate with longer use, plateau, or eventually fade due to neuroadaptation is unstudied.
- Disease-modification claims in established Alzheimer's are not supported. The Mori 2009 evidence is for mild cognitive impairment, not established dementia, and the one erinacine-A trial in mild Alzheimer's disease (Li 2020) was a pilot study. The evidence does not support presenting Lion's Mane as a treatment for Alzheimer's dementia.
- Product variability is substantial. A trial conducted with 96% fruit-body powder does not validate every Lion's Mane product on the market. Mycelium-on-grain products may have low actual mushroom content and untested clinical efficacy.
- Young healthy adults are not the validated population. Marketing claims targeting students and young professionals outrun the actual evidence, which is specifically in older adults.
- The pooled numbers are modest. A 2025 systematic review (PubMed searched from January 2000 to June 2024) found five randomized controlled trials. Mini-Mental State Examination scores from one randomized controlled trial and one pilot clinical trial showed a combined weighted mean increase of 1.17 in the Lion's Mane groups.
- No placebo-controlled trial has demonstrated reduction in conversion from MCI to dementia. This would be the definitive disease-modification trial, requires several years of follow-up, and has not been done.
A reasonable summary: Lion's Mane has the best controlled-trial evidence base of any dietary mushroom for cognitive function. In mild cognitive impairment the evidence is one small positive trial with no adverse laboratory findings, set beside conventional cardiovascular risk reduction, exercise, sleep optimization, and treatment of any reversible contributors, which carry their own evidence. It does not support disease-modification claims in established dementia or guaranteed benefit in young healthy adults.
Key Research Papers
- Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T (2009). Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytotherapy Research. 23(3):367-72. — PubMed PMID: 18844328
- Saitsu Y, Nishide A, Kikushima K, Shimizu K, Ohnuki K (2019). Improvement of cognitive functions by oral intake of Hericium erinaceus. Biomedical Research. 40(4):125-131. — PubMed PMID: 31413233
- Tsai-Teng T, Chin-Chu C, Li-Ya L, Wan-Ping C, Chung-Kuang L, Chien-Chang S, Chi-Ying HF, Chien-Chih C, Shiao YJ (2016). Erinacine A-enriched Hericium erinaceus mycelium ameliorates Alzheimer's disease-related pathologies in APPswe/PS1dE9 transgenic mice. Journal of Biomedical Science. 23(1):49. — PubMed PMID: 27350344
- Li IC, Chang HH, Lin CH, Chen WP, Lu TH, Lee LY, Chen YW, Chen YP, Chen CC, Lin DP (2020). Prevention of early Alzheimer's disease by erinacine A-enriched Hericium erinaceus mycelia pilot double-blind placebo-controlled study. Frontiers in Aging Neuroscience. 12:155. — PubMed PMID: 32581767
- Mori K, Obara Y, Moriya T, Inatomi S, Nakahata N (2011). Effects of Hericium erinaceus on amyloid-beta(25-35) peptide-induced learning and memory deficits in mice. Biomedical Research. 32(1):67-72. — PubMed PMID: 21383512
- Mori K, Obara Y, Hirota M, Azumi Y, Kinugasa S, Inatomi S, Nakahata N (2008). Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells. Biological & Pharmaceutical Bulletin. 31(9):1727-32. — PubMed PMID: 18758067
- Lai PL, Naidu M, Sabaratnam V, Wong KH, David RP, Kuppusamy UR, Abdullah N, Malek SN (2013). Neurotrophic properties of the Lion's mane medicinal mushroom, Hericium erinaceus (Higher Basidiomycetes) from Malaysia. International Journal of Medicinal Mushrooms. 15(6):539-54. — PubMed PMID: 24266378
- Nagano M, Shimizu K, Kondo R, Hayashi C, Sato D, Kitagawa K, Ohnuki K (2010). Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomedical Research. 31(4):231-7. — PubMed PMID: 20834180
- Vigna L, Morelli F, Agnelli GM, Napolitano F, Ratto D, Occhinegro A, Di Iorio C, Savino E, Girometta C, Brandalise F, Rossi P (2019). Hericium erinaceus improves mood and sleep disorders in patients affected by overweight or obesity: could circulating pro-BDNF and BDNF be potential biomarkers? Evidence-Based Complementary and Alternative Medicine. 2019:7861297. — PubMed PMID: 31118969
- Docherty S, Doughty FL, Smith EF (2023). The acute and chronic effects of Lion's Mane mushroom supplementation on cognitive function, stress and mood in young adults: a double-blind, parallel groups, pilot study. Nutrients. 15(22):4842. — PubMed PMID: 38004235
- Surendran G, Saye J, Binti Mohd Jalil S, Spreadborough J, Duong K, Shatwan IM, Lilley D, Heinrich M, Dodd GF, Surendran S (2025). Acute effects of a standardised extract of Hericium erinaceus (Lion's Mane mushroom) on cognition and mood in healthy younger adults: a double-blind randomised placebo-controlled study. Frontiers in Nutrition. 12:1405796. — PubMed PMID: 40276537
- Menon A, Jalal A, Arshad Z, Nawaz FA, Kashyap R (2025). Benefits, side effects, and uses of Hericium erinaceus as a supplement: a systematic review. Frontiers in Nutrition. 12:1641246. — PubMed PMID: 40959699
- Friedman M (2015). Chemistry, nutrition, and health-promoting properties of Hericium erinaceus (Lion's Mane) mushroom fruiting bodies and mycelia and their bioactive compounds. Journal of Agricultural and Food Chemistry. 63(32):7108-23. — PubMed PMID: 26244378
- Petersen RC (2004). Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine. 256(3):183-94. — PubMed PMID: 15324362
- Imai Y, Hasegawa K (1994). The Revised Hasegawa Dementia Scale (HDS-R). Journal of the Hong Kong College of Psychiatrists. 4(SP2):20-24. (Not indexed in PubMed.)
- Phan CW, David P, Naidu M, Wong KH, Sabaratnam V (2015). Therapeutic potential of culinary-medicinal mushrooms for the management of neurodegenerative diseases: diversity, metabolite, and mechanism. Critical Reviews in Biotechnology. 35(3):355-68. — PubMed PMID: 24654802
- Spelman K, Sutherland E, Bagade A (2017). Neurological activity of Lion's Mane (Hericium erinaceus). Journal of Restorative Medicine. 6(1):19-26. — doi:10.14200/jrm.2017.6.0108
PubMed Topic Searches
Connections
- Lion's Mane Overview
- Lion's Mane Benefits Hub
- Lion's Mane for NGF
- Lion's Mane for Mood & Depression
- Lion's Mane for Gut Health
- Alzheimer's Disease
- Dementia
- Parkinson's Disease
- Depression
- Omega-3 Fatty Acids
- Vitamin D3
- Ashwagandha
- Reishi Mushroom
- Turkey Tail Mushroom
- Chaga Mushroom
- Gut-Brain Axis
- History